Seminars in respiratory and critical care medicine最新文献_第3页

Bronchoscopic Lung Volume Reduction: A Review. 支气管镜肺容积缩小术：综述。

IF 2.3 3区医学

Seminars in respiratory and critical care medicine Pub Date : 2024-07-18 DOI: 10.1055/s-0044-1787876

Shreya Podder, Marium Khan, Zane Sink, Steven Verga, Jonathan S Kurman, Elizabeth Malsin

{"title":"Bronchoscopic Lung Volume Reduction: A Review.","authors":"Shreya Podder, Marium Khan, Zane Sink, Steven Verga, Jonathan S Kurman, Elizabeth Malsin","doi":"10.1055/s-0044-1787876","DOIUrl":"https://doi.org/10.1055/s-0044-1787876","url":null,"abstract":"Bronchoscopic lung volume reduction (BLVR) is an established treatment modality for the management of advanced chronic obstructive pulmonary disease complicated by severe emphysema and hyperinflation refractory to other therapies. BLVR aims to reduce hyperinflation and residual volume, thereby improving pulmonary function, symptom control, and quality of life. Multiple distinct devices and technologies, including endobronchial coils, thermal vapor ablation, bio-lung volume reduction, and airway bypass stenting, have been developed to achieve lung volume reduction with varying degrees of accessibility and evidence. The most promising BLVR treatment modality to date has been the placement of one-way endobronchial valves (EBVs), with more than 25,000 cases performed worldwide. Identifying symptomatic patients who would benefit from BLVR is challenging and can be time and resource intensive, and candidacy may be limited by physiologic parameters. Additional new technologies may be able to improve the identification and evaluation of candidates as well as increase the portion of evaluated patients who ultimately qualify for BLVR. In this review, we aim to provide historical context to BLVR, summarize the available evidence regarding its use, discuss potential complications, and provide readers with a clear guide to patient selection and referral for BLVR, with a focus on EBV placement. In addition, we will highlight potential future directions for the field.","PeriodicalId":21727,"journal":{"name":"Seminars in respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Marijuana Use on Lung Health. 吸食大麻对肺部健康的影响。

IF 2.3 3区医学

Seminars in respiratory and critical care medicine Pub Date : 2024-07-05 DOI: 10.1055/s-0044-1785679

Joanne M Bando, Donald P Tashkin, Igor Z Barjaktarevic

{"title":"Impact of Marijuana Use on Lung Health.","authors":"Joanne M Bando, Donald P Tashkin, Igor Z Barjaktarevic","doi":"10.1055/s-0044-1785679","DOIUrl":"https://doi.org/10.1055/s-0044-1785679","url":null,"abstract":"The widespread use of marijuana in the context of increasing legalization has both short- and long-term health implications. Although various modes of marijuana use-smoked, vaped, or ingested-may lead to a wide scope of potential systemic effects, we focus here on inhalational use of marijuana as the most common mode with the lung as the organ that is most directly exposed to its effects. Smoked marijuana has been associated with symptoms of chronic bronchitis and histopathologic changes in airway epithelium, but without consistent evidence of long-term decline in pulmonary function. Its role in immunomodulation, both for risk of infection and protection against a hyperinflammatory host response to infection, has been suggested in animal models and in vitro without conclusive extrapolation to humans. Marijuana smoke contains carcinogens like those found in tobacco, raising concern about its role in lung cancer, but evidence is mixed and made challenging by concurrent tobacco use. Vaping may offer a potential degree of harm reduction when compared with smoking marijuana with reduction of exposure to several toxins, including carbon monoxide, and reduction in chronic respiratory symptoms. However, these potential benefits are counterbalanced by risks including vaping-associated lung injury, potentially more intense drug exposure, and other yet not well-understood toxicities. As more states legalize marijuana and the federal government considers changing this from a Schedule I to a Schedule III controlled substance, we anticipate an increase in prospective medical studies concerning the risks related to marijuana use. This review is based on currently available data concerning the impact of inhaled marijuana on lung health.","PeriodicalId":21727,"journal":{"name":"Seminars in respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing Interventions for Chronic Obstructive Pulmonary Disease. 制定慢性阻塞性肺病干预措施。

IF 2.3 3区医学

Seminars in respiratory and critical care medicine Pub Date : 2024-07-05 DOI: 10.1055/s-0044-1787875

Audra J Schwalk, Niral M Patel, Nagendra Y Madisi

{"title":"Developing Interventions for Chronic Obstructive Pulmonary Disease.","authors":"Audra J Schwalk, Niral M Patel, Nagendra Y Madisi","doi":"10.1055/s-0044-1787875","DOIUrl":"https://doi.org/10.1055/s-0044-1787875","url":null,"abstract":"Chronic obstructive pulmonary disease (COPD) is an incurable, progressive respiratory disease that may have a significant negative impact on the morbidity and mortality of affected patients. A substantial portion of the world's population is affected by COPD, and despite optimal medical management with medications, supplemental oxygen, and pulmonary rehabilitation, many patients are left debilitated because of this disease. Bronchoscopic treatment modalities offer a less-invasive method for the treatment of refractory COPD compared to surgical interventions and have expanded the potential therapeutic options for these patients. Bronchoscopic lung volume reduction is aimed at decreasing the hyperinflation and air trapping that occur in emphysema, and the most studied and successful intervention is endobronchial valve placement. Endobronchial coils, polymeric sealants, and thermal ablation are other researched alternatives. Additional interventional procedures are being investigated for the treatment of the mucus hypersecretion and cough that are associated with the chronic bronchitis phenotype of COPD and include targeted lung denervation, metered dose spray cryotherapy, deobstruction balloon, and bronchial rheoplasty. This review summarizes the most recent evidence pertaining to available therapies for the management of COPD, including chronic bronchitis, with a particular focus on bronchoscopic interventions.","PeriodicalId":21727,"journal":{"name":"Seminars in respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Therapeutic Approaches in Connective Tissue Disease-Associated Interstitial Lung Disease. 结缔组织病相关间质性肺病的新型治疗方法

IF 3.2 3区医学

Seminars in respiratory and critical care medicine Pub Date : 2024-06-01 Epub Date: 2024-05-13 DOI: 10.1055/s-0044-1786155

Erica Mulcaire-Jones, Janelle Vu Pugashetti, Justin M Oldham, Dinesh Khanna

引用次数: 0

Pulmonary Hypertension in Connective Tissue Diseases Other than Systemic Sclerosis. 系统性硬化症以外的结缔组织疾病中的肺动脉高压。

IF 3.2 3区医学

Seminars in respiratory and critical care medicine Pub Date : 2024-06-01 Epub Date: 2024-03-18 DOI: 10.1055/s-0044-1782217

Brandon Budhram, Jason Weatherald, Marc Humbert

{"title":"Pulmonary Hypertension in Connective Tissue Diseases Other than Systemic Sclerosis.","authors":"Brandon Budhram, Jason Weatherald, Marc Humbert","doi":"10.1055/s-0044-1782217","DOIUrl":"10.1055/s-0044-1782217","url":null,"abstract":"Pulmonary hypertension (PH) is a known complication of certain connective tissue diseases (CTDs), with systemic sclerosis (SSc) being the most common in the Western world. However, PH in association with non-SSc CTD such as systemic lupus erythematous, mixed connective tissue disease, and primary Sjögren's syndrome constitutes a distinct subset of patients with inherently different epidemiologic profiles, pathophysiologic mechanisms, clinical features, therapeutic options, and prognostic implications. The purpose of this review is to inform a practical approach for clinicians evaluating patients with non-SSc CTD-associated PH.The development of PH in these patients involves a complex interplay between genetic factors, immune-mediated mechanisms, and endothelial cell dysfunction. Furthermore, the broad spectrum of CTD manifestations can contribute to the development of PH through various pathophysiologic mechanisms, including intrinsic pulmonary arteriolar vasculopathy (pulmonary arterial hypertension, Group 1 PH), left-heart disease (Group 2), chronic lung disease (Group 3), chronic pulmonary artery obstruction (Group 4), and unclear and/or multifactorial mechanisms (Group 5). The importance of diagnosing PH early in symptomatic patients with non-SSc CTD is highlighted, with a review of the relevant biomarkers, imaging, and diagnostic procedures required to establish a diagnosis.Therapeutic strategies for non-SSc PH associated with CTD are explored with an in-depth review of the medical, interventional, and surgical options available to these patients, emphasizing the CTD-specific considerations that guide treatment and aid in prognosis. By identifying gaps in the current literature, we offer insights into future research priorities that may prove valuable for patients with PH associated with non-SSc CTD.","PeriodicalId":21727,"journal":{"name":"Seminars in respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140158951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Approach to Pulmonary Nodules in Connective Tissue Disease. 结缔组织病肺部结节的治疗方法。

IF 3.2 3区医学

Seminars in respiratory and critical care medicine Pub Date : 2024-06-01 Epub Date: 2024-03-28 DOI: 10.1055/s-0044-1782656

Brian Gaffney, David J Murphy

引用次数: 0

Review of Pulmonary Manifestations in Antisynthetase Syndrome. 抗合成代谢酶综合征肺部表现回顾。

IF 3.2 3区医学

Seminars in respiratory and critical care medicine Pub Date : 2024-06-01 Epub Date: 2024-05-06 DOI: 10.1055/s-0044-1785536

Mohammad I Ghanbar, Sonye K Danoff

{"title":"Review of Pulmonary Manifestations in Antisynthetase Syndrome.","authors":"Mohammad I Ghanbar, Sonye K Danoff","doi":"10.1055/s-0044-1785536","DOIUrl":"10.1055/s-0044-1785536","url":null,"abstract":"Antisynthetase syndrome (ASyS) is now a widely recognized entity within the spectrum of idiopathic inflammatory myopathies. Initially described in patients with a triad of myositis, arthritis, and interstitial lung disease (ILD), its presentation can be diverse. Additional common symptoms experienced by patients with ASyS include Raynaud's phenomenon, mechanic's hand, and fever. Although there is a significant overlap with polymyositis and dermatomyositis, the key distinction lies in the presence of antisynthetase antibodies (ASAs). Up to 10 ASAs have been identified to correlate with a presentation of ASyS, each having manifestations that may slightly differ from others. Despite the proposal of three classification criteria to aid diagnosis, the heterogeneous nature of patient presentations poses challenges. ILD confers a significant burden in patients with ASyS, sometimes manifesting in isolation. Notably, ILD is also often the initial presentation of ASyS, requiring pulmonologists to remain vigilant for an accurate diagnosis. This article will comprehensively review the various aspects of ASyS, including disease presentation, diagnosis, management, and clinical course, with a primary focus on its pulmonary manifestations.","PeriodicalId":21727,"journal":{"name":"Seminars in respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140866265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pleural Diseases in Connective Tissue Diseases. 结缔组织疾病中的胸膜疾病。

IF 3.2 3区医学

Seminars in respiratory and critical care medicine Pub Date : 2024-06-01 Epub Date: 2024-03-28 DOI: 10.1055/s-0044-1782612

Hui Guo, Beenish Iqbal, Najib M Rahman

引用次数: 0

Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment. 类风湿性关节炎相关间质性肺病及其治疗概述。

IF 2.3 3区医学

Seminars in respiratory and critical care medicine Pub Date : 2024-06-01 Epub Date: 2024-03-14 DOI: 10.1055/s-0044-1782218

Janelle Vu Pugashetti, Joyce S Lee

{"title":"Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment.","authors":"Janelle Vu Pugashetti, Joyce S Lee","doi":"10.1055/s-0044-1782218","DOIUrl":"10.1055/s-0044-1782218","url":null,"abstract":"Interstitial lung disease (ILD) is a common pulmonary complication of rheumatoid arthritis (RA), causing significant morbidity and mortality. Optimal treatment for RA-ILD is not yet well defined. Reliable prognostic indicators are largely byproducts of prior ILD progression, including low or decreasing forced vital capacity and extensive or worsening fibrosis on imaging. In the absence of validated tools to predict treatment response, decisions about whether to initiate or augment treatment are instead based on clinical judgment. In general, treatment should be initiated in patients who are symptomatic, progressing, or at high risk of poor outcomes. Retrospective data suggest that mycophenolate mofetil, azathioprine, and rituximab are likely effective therapies for RA-ILD. Abatacept is also emerging as a potential first-line treatment option for patients with RA-ILD. Further, recent data demonstrate that immunosuppression may be beneficial even in patients with a usual interstitial pneumonia (UIP) pattern on imaging, suggesting that immunosuppression should be considered irrespective of imaging pattern. Recent randomized controlled trials have shown that antifibrotic medications, such as nintedanib and likely pirfenidone, slow forced vital capacity decline in RA-ILD. Consideration can be given to antifibrotic initiation in patients progressing despite immunosuppression, particularly in patients with a UIP pattern. Future research directions include developing tools to predict which patients will remain stable from patients who will progress, discriminating patients who will respond to treatment from nonresponders, and developing algorithms for starting immunosuppression, antifibrotics, or both as first-line therapies.","PeriodicalId":21727,"journal":{"name":"Seminars in respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140132543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic Lupus Erythematosus-related Lung Disease. 系统性红斑狼疮相关肺病

IF 3.2 3区医学

Seminars in respiratory and critical care medicine Pub Date : 2024-06-01 Epub Date: 2024-03-28 DOI: 10.1055/s-0044-1782653

Elisabeth Bendstrup, Evelyn Lynn, Anne Troldborg

引用次数: 0